Xeris Biopharma Holdings (XERS) Total Debt (2023 - 2025)
Historic Total Debt for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2025 value amounting to $219.5 million.
- Xeris Biopharma Holdings' Total Debt rose 135758.78% to $219.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.5 million, marking a year-over-year increase of 135758.78%. This contributed to the annual value of $232.1 million for FY2024, which is 1050.6% up from last year.
- Per Xeris Biopharma Holdings' latest filing, its Total Debt stood at $219.5 million for Q3 2025, which was up 135758.78% from $218.6 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' Total Debt ranged from a high of $232.1 million in Q4 2024 and a low of $420000.0 during Q2 2024
- In the last 3 years, Xeris Biopharma Holdings' Total Debt had a median value of $17.5 million in 2023 and averaged $106.9 million.
- In the last 5 years, Xeris Biopharma Holdings' Total Debt tumbled by 9747.55% in 2024 and then skyrocketed by 5195380.95% in 2025.
- Xeris Biopharma Holdings' Total Debt (Quarter) stood at $210.0 million in 2023, then grew by 10.51% to $232.1 million in 2024, then dropped by 5.45% to $219.5 million in 2025.
- Its Total Debt stands at $219.5 million for Q3 2025, versus $218.6 million for Q2 2025 and $229.8 million for Q1 2025.